Search clinical trials for: high risk localized adenocarcinoma of the prostate

Total 449703 results

University of Chicago

Recruiting

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

Prostate Cancer | Prostate Adenocarcinoma

United States
Centre Georges Francois Leclerc

Recruiting

Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk (SHORT)

To Evaluate the Rate of Digestive and Urinary Toxicity

France
Advocate Health Care

Recruiting

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

Prostate Adenocarcinoma

United States
Sir Mortimer B. Davis - Jewish General Hospital
Abbott

Recruiting

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

Adenocarcinoma of the Prostate

Canada
UNICANCER
Sanofi

Active, not recruiting

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse (PEACE2)

Adenocarcinoma of Prostate | Progression of Prostate Cancer

France
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute

Active, not recruiting

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

Prostate Cancer

United States
Jonsson Comprehensive Cancer Center

Active, not recruiting

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
NCIC Clinical Trials Group

Terminated

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer (DART)

Prostate Cancer

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical... and other collaborators

Active, not recruiting

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Prostate Cancer

United States, Canada
University of Washington
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Gene Expression Analysis in Patients Undergoing Surgery For High-Risk Localized Prostate Cancer

Stage II Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate

United States
UNC Lineberger Comprehensive Cancer Center
Sanofi

Completed

Docetaxel, Androgen Ablation, and External-Beam Radiation Therapy in Patients With High-Risk Localized Prostate Cancer (NRR)

Prostate Cancer

United States
Myrexis Inc.

Unknown

R-Flurbiprofen in Treating Patients With Localized Prostate Cancer at Risk of Recurrence

Prostate Cancer

United States
Region Skane

Recruiting

Tumor-directed Radiation Therapy for Patients With the Highest Risk Category of Localized Prostate Cancer

Prostate Cancer

Sweden
British Columbia Cancer Agency
University of British Columbia; Vancouver Prostate Centre; BC Cancer Foundation

Recruiting

Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer (BrachyTRACKS)

Localized Prostate Carcinoma

Canada
Comprehensive Cancer Centre The Netherlands

Recruiting

High-Risk prostatE Cancer radiatiOn Versus surgERy (RECOVER)

Prostate Cancer | Prostate Adenocarcinoma

Netherlands
Ottawa Hospital Research Institute
Knight Therapeutics (USA) Inc

Recruiting

Dose Escalation For INtraprostatic LEsions (DEFINE)

Prostatic Neoplasms

Canada
Genesis Research LLC

Recruiting

Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging

Prostate Cancer | Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
National Cancer Institute (NCI)

Recruiting

T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Cancer Of Prostate

United States
The Affiliated Nanjing Drum Tower Hospital of Nanjing...
First Affiliated Hospital of Zhejiang University; The First Affiliated Hospital...

Recruiting

Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer

Prostate Cancer

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Prostate Adenocarcinoma

United States, Canada
Profound Medical Inc.

Recruiting

A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer (CAPTAIN)

Prostate Cancer | Prostate Adenocarcinoma

United States, Canada, Finland
M.D. Anderson Cancer Center

Recruiting

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States
Washington University School of Medicine
The Foundation for Barnes-Jewish Hospital

Not yet recruiting

Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer

Prostate Cancer | Cancer of Prostate

United States
Daniel George, MD
Merck Sharp & Dohme LLC

Not yet recruiting

Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON) (TALON)

Prostate Cancer

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Prostate Adenocarcinoma | Metastatic Malignant Neoplasm in the Bone | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

United States, Canada
University of Virginia

Recruiting

EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer (Prostate005)

Prostate Cancer | Prostate Adenocarcinoma

United States
Westfälische Wilhelms-Universität Münster
Janssen Pharmaceutica N.V., Belgium

Recruiting

Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (ADAM)

Prostatic Neoplasms

Austria, Germany
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Recruiting

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Prostatic Neoplasms

United States, France, Poland, Taiwan, Ukraine, United Kingdom, China, Belgium, Germany, Spain, Israel, Mexico, Malaysia, Romania, Turkey, Canada, Netherlands, Korea, Republic of, Brazil, Russian Federation, Argentina, Sweden, Czechia
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Stage III Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)

Prostatic Neoplasms

United States, Italy, Czechia, Israel, Japan, Taiwan, Korea, Republic of, United Kingdom, France, Spain, Germany, Australia, Canada, Brazil, Netherlands, Russian Federation, Argentina, Poland
University of Florida

Active, not recruiting

Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer (PR11)

Adenocarcinoma of the Prostate

United States
European Organisation for Research and Treatment...

Active, not recruiting

Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (PEGASUS)

Prostate Cancer

Germany, Spain, France, Belgium, United Kingdom, Switzerland, Italy, Denmark
Memorial Sloan Kettering Cancer Center
Ferring Pharmaceuticals

Active, not recruiting

Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

Prostate Cancer | Prostatic Adenocarcinoma

United States
Hospices Civils de Lyon

Active, not recruiting

Efficacy Evaluation of Focused HIFU (High Intensity Focused Ultrasound) Therapy in Patients With Localized Intermediate Risk Prostate Cancer (FOCALE)

Prostate Cancer

France, Sweden
NRG Oncology
National Cancer Institute (NCI)

Suspended

Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer (NADIR)

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8

Canada, United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
University of California, San Francisco

Active, not recruiting

Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer

Prostate Cancer | Radiation Toxicity

United States
University Health Network, Toronto

Completed

Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate

Adenocarcinoma of the Prostate

Canada
Thomas Jefferson University

Suspended

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

Prostate Adenocarcinoma | Stage IIIB Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8

United States
Mayo Clinic

Active, not recruiting

Prospective Evaluation of Hypofractionation Proton Beam Therapy With Concurrent Treatment of the Prostate and Pelvic Nodes for Clinically Localized, High Risk or Unfavorable Intermediate Risk Prostate Cancer

Prostate Cancer

United States
David VanderWeele

Terminated

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer (ADDItion)

Castrate Resistant Prostate Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Astellas Pharma Inc; Medivation, Inc.

Active, not recruiting

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

Recurrent Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIB Prostate Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

Prostate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8

United States
Johnson & Johnson International (Singapore) Pte...

Completed

A Study of High Risk Localized Prostate Cancer Participants Treated With Radical Prostatectomy and Perioperative Hormonal Therapy (ACE)

High Risk Localized Prostate Cancer

Japan, Korea, Republic of, Taiwan
British Columbia Cancer Agency

Active, not recruiting

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

Prostate Cancer

Canada
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer

Prostate Cancer

United States, Canada
H. Lee Moffitt Cancer Center and Research Institute

Completed

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

Prostate Cancer

United States
Brown University
The Miriam Hospital; Rhode Island Hospital

Completed

Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer

Prostate Cancer

United States

Search clinical trials for: high risk localized adenocarcinoma of the prostate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations